E16AD7E1-29DA-4B8F-8B12-A8A6BBAA9174
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.918528252299605
- age_years
- 38
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.547
- MYC_TARGETS_V1+0.495
- MYC_TARGETS_V2+0.475
- INTERFERON_GAMMA_RESPONSE+0.433
- PROTEIN_SECRETION+0.368
- NOTCH_SIGNALING+0.364
- UNFOLDED_PROTEIN_RESPONSE+0.360
- DNA_REPAIR+0.353
- ALLOGRAFT_REJECTION+0.352
- OXIDATIVE_PHOSPHORYLATION+0.308
Top 10 suppressed
- KRAS_SIGNALING_DN-0.409
- ANGIOGENESIS-0.377
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- MYOGENESIS-0.312
- SPERMATOGENESIS-0.305
- COAGULATION-0.241
- APICAL_JUNCTION-0.219
- HYPOXIA-0.211
- ESTROGEN_RESPONSE_LATE-0.167
- ESTROGEN_RESPONSE_EARLY-0.156
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.914 |
| 2 | 37DF227E-8B22-4757-A65C-87C6F28F87D4 | — | — | 0.908 |
| 3 | 37E6F027-C405-4671-80BD-CC40684DE803 | — | — | 0.903 |
| 4 | SRR934891 | — | — | 0.893 |
| 5 | 7E7AAFFD-6EEB-4357-88AD-9EB12BB78602 | — | — | 0.881 |
| 6 | 76987B28-B56B-4A1F-B77C-1E08B8EFEF90 | — | — | 0.875 |
| 7 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.861 |
| 8 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.856 |
| 9 | 27C775C6-ABAD-44BE-B995-21DC4C68C399 | — | — | 0.855 |
| 10 | E0173AAB-678A-46E0-B701-C79A6BE9B9D8 | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.547 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.495 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.475 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.433 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.368 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.364 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.353 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.352 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.308 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.298 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.292 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.282 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.272 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.211 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.204 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.197 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.173 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.128 | Idelalisib | — uncovered |